Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.78 |
| ▸ | DPP7 | Q9UHL4 | 15/20 | 0.78 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 0.78 |
| ▸ | FAP | Q12884 | 12/20 | 0.78 |
| ▸ | DPP9 | Q86TI2 | 11/20 | 0.78 |
| ▸ | PREP | P48147 | 3/20 | 0.60 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223957 | 0.87 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL7940093 | 0.87 | DPP4 (0.64) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL12323655 | 0.87 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL12286144 | 0.87 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL12286143 | 0.87 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL12340775 | 0.86 | DPP4 (0.85) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL3092652 | 0.86 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL7938765 | 0.86 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL3092661 | 0.86 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL15334549 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072830-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072830-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| WO-2006034435-A2 | METHODS AND COMPOSITIONS FOR TREATING GLUCOSE-ASSOCIATED CONDITIONS, METABOLIC SYNDROME, DYSLIPIDEMIAS AND OTHER CONDITIONS | POINT THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063719-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| US-20060063719-A1 | Methods for treating diabetes | POINT THERAPEUTICS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063719-A1 | Methods for treating diabetes | IAPP, SLC5A2, SLC2A3 | DPP4 5/4885DPP7 21/4885DPP8 51/4885 |
| US-20070072830-A1 | Methods for treating diabetes | IAPP, SLC5A2, SLC2A3 | DPP4 5/4885DPP7 21/4885DPP8 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.